BOLT
Bolt Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
6.17 / 10
Outperform
Analyst coverage is limited to one strong‑buy recommendation, with a 50% historical win rate. Fund‑flow scores 7.28/10, showing strong inflows from small and medium investors but overall negative trends in larger blocks, indicating mixed capital dynamics.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-13
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for BOLT?
- BOLT holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.17/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
